Picture of Trans Lux logo

TNLX — Trans Lux News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

Australia's Telix Pharma posts worst day in four months on discounted placement

** Cancer-related drugmaker Telix Pharmaceuticals Ltd
 TLX.AX  fall as much as 15.7% to A$6.82, marks its worst
intraday session since Sept 23
    ** Co announces https://telixpharma.com/investors placement
of 22.7 mln shares at A$7.70 apiece to raise A$175 mln ($125.65
mln)
    ** Issue price represents a discount of 4.8% to TLX's close
of A$8.09 on Jan 19, stock was on a trading halt since Jan 20
    ** Says will use funds to execute its late-stage clinical
product pipeline and advance its multiple program towards
commercialisation
    ** Newly issued shares represent about 13% of co's free
float of 176.2 mln shares, according to Refinitiv data
    ** TLX hits lowest level since Dec 7
    ** More than 5.6 mln shares change hands, vs the 30-day
average of 610,600 shares
    ** TLX up 4.4% this year, as of last close

    ($1 = 1.3928 Australian dollars)

 (Reporting by Sameer Manekar in Bengaluru)
 ((Sameer.Manekar@thomsonreuters.com; Twitter: https://twitter.com/sameer_manekar))

Recent news on Trans Lux

See all news